GlassScriptPhysician profile
Elaine M Crain
NPI 1649385444
$4,318.39
in general payments reported to CMS, 2019-2025
37 companies · $2,021 in 2025
The $2,021 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $353 · 2022: $498 · 2023: $352 · 2024: $1,095 · 2025: $2,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,466.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $572.77 | 2024-2025 | Evenity, Repatha, Tavneos |
| Abbvie INC. | $533.78 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $253.36 | 2021-2025 | Airsupra |
| Boston Scientific Corporation | $241.69 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Otsuka America Pharmaceutical, INC. | $235.75 | 2022-2024 | Rexulti |
| Novo Nordisk INC | $202.75 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $171.03 | 2024-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $138.46 | 2024 | Voquezna |
| Cequr Corporation | $121.88 | 2025 | Cequr Simplicity |
| Sobi, INC | $120.24 | 2025 | |
| Alexion Pharmaceuticals, INC. | $117.83 | 2025 | |
| Axsome Therapeutics, INC. | $115.18 | 2024-2025 | Symbravo, Auvelity |
| Neurocrine Biosciences, INC. | $107.34 | 2024 | Ingrezza |
| Medtronic, INC. | $104.27 | 2025 | Symplicity G3 |
| Actelion Pharmaceuticals US, INC. | $103.91 | 2025 | Opsumit, Uptravi |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $103.73 | 2022 | |
| Kyowa Kirin, INC. | $102.82 | 2025 | |
| Neurelis, INC. | $98.20 | 2023-2024 | Valtoco |
| Sanofi-Aventis U.S. LLC | $95.40 | 2024 | |
| Pfizer INC. | $89.52 | 2024-2025 | |
| Myovant Sciences INC. | $87.70 | 2022 | |
| Shield Therapeutics INC | $84.40 | 2023 | Accrufer |
| Corcept Therapeutics | $50.16 | 2025 | Korlym |
| Globus Medical, INC. | $48.70 | 2025 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.20 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $43.69 | 2025 | The Cologuard Plus Collection Kit |
| Biogen, INC. | $40.42 | 2022 | |
| Lilly USA, LLC | $38.90 | 2025 | Kisunla |
| Takeda Pharmaceuticals U.S.A., INC. | $35.70 | 2025 | Trintellix |
| Inspire Medical Systems, INC. | $35.59 | 2025 | Inspire |
| Lundbeck LLC | $31.86 | 2025 | Vyepti |
| Nevro Corp. | $30.36 | 2024 | Senza |
| Merck Sharp & Dohme LLC | $28.81 | 2025 | Gardasil 9, Capvaxive |
| Abbott Laboratories | $23.93 | 2025 | Freestyle Libre 3 |
| Tms Neurohealth Centers INC. | $20.73 | 2025 | Tms Neurohealth Centers INC. |
| Dexcom, INC. | $20.31 | 2025 | Dexcom G6 Transmitter |
| Seqirus USA INC | $20.02 | 2024 | Fluad, Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elaine Crain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.